WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) has approved Crenessity (crinecerfont) for use alongside glucocorticoids in managing classic congenital adrenal hyperplasia (CAH ...
its experimental therapy for congenital adrenal hyperplasia (CAH). CAH, a group of genetic disorders affecting adrenal glands, is characterized by excessive levels of androstenedione (A4), a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback